Experience Matters: Creative Solutions to Overcome Challenges in Antibody Drug Discovery
PEGS Boston Virtual 2021 Presentation
Generating molecularly-diverse drug-quality antibodies can be difficult when working with challenging targets. AlivaMab Discovery Services combines Ablexis’ AlivaMab® Mouse, the leading platform for successful human therapeutic antibody discovery, with innovative technologies and deep expertise to deliver superior antibody therapeutics in rapid timelines – even for challenging targets. Watch as we review our antibody discovery approaches for challenging targets which yielded diverse leads.
Larry Green, Ph.D., CEO, Ablexis
John “Lippy” Lippincott, Ph.D., VP of Research, AlivaMab Discovery Services